Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient

Am J Transplant. 2015 Mar;15(3):827-32. doi: 10.1111/ajt.13023. Epub 2015 Feb 3.

Abstract

Cytomegalovirus (CMV) is a significant cause of morbidity, mortality and graft loss in solid organ transplantation (SOT). Treatment options for ganciclovir-resistant CMV are limited. We describe a case of ganciclovir-resistant CMV disease in a renal transplant recipient manifested by thrombotic microangiopathy-associated glomerulopathy. Adoptive T cell immunotherapy using CMV-specific T cells from a donor bank was used as salvage therapy. This report is a proof-of-concept of the clinical and logistical feasibility of this therapy in SOT recipients.

Keywords: antibiotic drug resistance; antibiotic: antiviral-ganciclovir/valganciclovir; clinical research/practice; infection and infectious agents; infectious disease; kidney transplantation/nephrology; viral: Cytomegalovirus (CMV).

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / therapy*
  • Ganciclovir / therapeutic use*
  • Humans
  • Immunotherapy, Adoptive*
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • T-Lymphocytes / cytology*

Substances

  • Antiviral Agents
  • Ganciclovir